Conivaptan: Evidence supporting its therapeutic use in hyponatremia

References

• Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol. 1997;272:F3–F12.
   PubMed Web of Science ®Google Scholar
• Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am. 1997;81:585–609.
   PubMed Web of Science ®Google Scholar
• Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–542.
   PubMed Web of Science ®Google Scholar
• Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29:1–9.
   PubMed Web of Science ®Google Scholar
• Rai A, Whaley-Connell A, McFarlane S, et al. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol. 2006;26:579–589.
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30–S35.
   Google Scholar
• Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. 2003;18:3–8.
   PubMedGoogle Scholar
• Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69:2124–2130.
   PubMed Web of Science ®Google Scholar
• Vaprisol (conivaptan HCl injection). Package insert. Deerfield IL: Astellas Tokai Co.; February 2006.
   Google Scholar
• Risvanis J, Naitoh M, Johnston CI, Burrell LM. In vivo and in vitro characterization of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat. Eur J Pharmacol. 1999;381:23–30.
   PubMed Web of Science ®Google Scholar
• Burnier M, Fricker AF, Hayoz D, et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol. 1999; 55:633–637.
   PubMed Web of Science ®Google Scholar
• Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110:582–584.
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GB, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104: 2417–2423.
   PubMed Web of Science ®Google Scholar
• Martinez-Castelao A. Conivaptan. Curr Opin Investig Drugs. 2002;3:89–95.
   PubMedGoogle Scholar
• Gross P, Bisaha JG, Smith N. Conivaptan, a novel V1A and V2 antagonist, increases serum sodium and effective water clearance in patients with hyponatremia. Circulation. 2004;110(Suppl 3):723 [abstract 3345].
   Google Scholar
• Ghali JK, Koren MJ, Tylor JR, et al; Conivaptan Study Group. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91:2145–2152.
   PubMed Web of Science ®Google Scholar
• Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447–457.
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolemic hyponatremia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf). 2008;69:159–168.
   PubMed Web of Science ®Google Scholar
• Ghali JK, Verbalis JG, McNutt B. Efficacy and safety of the vasopressin-receptor antagonist conivaptan hydrochloride injection in hyponatremic patients with and without underlying heart failure. San Francisco, CA: Oral session presentation at Endocrine Society Annual Conference; June 2008.
   Google Scholar
• Goldsmith SR, Francis GS, Cowley AW, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385–1390.
   PubMed Web of Science ®Google Scholar
• Rouleau J-L, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583–591.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR. Efficacy and safety of conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2006; 12(6)Suppl:S72.
   Web of Science ®Google Scholar
• Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J. 2003;145:179–186.
   PubMed Web of Science ®Google Scholar
• Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4:1522–1530.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1–S21.
   Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–191.
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Gulberg V, Gines P, et al; The VPA study group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
   PubMed Web of Science ®Google Scholar
• Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with Satavaptan (SR-121463B), an orally active non-peptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006; 1:1154–1160.
   PubMed Web of Science ®Google Scholar